{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T11:15:16Z","timestamp":1679483716067},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.1001\/jamaoncol.2022.4343","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T15:36:14Z","timestamp":1663860974000},"page":"1700","source":"Crossref","is-referenced-by-count":1,"title":["Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases"],"prefix":"10.1001","volume":"8","author":[{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Jinan University, Guangdong, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuixing","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Jinan University, Guangdong, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"cle220028r1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial.","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"15","key":"cle220028r2","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol"},{"issue":"32","key":"cle220028r3","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1200\/JCO.2012.45.1278","article-title":"Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant\/refractory epithelial ovarian cancer.","volume":"31","author":"Vergote","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"cle220028r4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jalz.2015.01.010","article-title":"Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment.","volume":"11","author":"Ithapu","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"cle220028r5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JAD-190822","article-title":"Machine learning predictive models can improve efficacy of clinical trials for Alzheimer\u2019s disease.","volume":"74","author":"Ezzati","year":"2020","journal-title":"J Alzheimers Dis"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2796769\/jamaoncology_zhang_2022_le_220028_1668658019.63578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:03:53Z","timestamp":1668701033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2796769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.4343","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}